- Home
- TIGR vs GYRE Comparison
TIGR vs GYRE Comparison
Compare TIGR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIGR
- GYRE
- Stock Information
- Founded
- TIGR 2014
- GYRE 2002
- Country
- TIGR Singapore
- GYRE United States
- Employees
- TIGR N/A
- GYRE N/A
- Industry
- TIGR Investment Bankers/Brokers/Service
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- TIGR Finance
- GYRE Health Care
- Exchange
- TIGR Nasdaq
- GYRE Nasdaq
- Market Cap
- TIGR 1.7B
- GYRE 897.1M
- IPO Year
- TIGR 2019
- GYRE N/A
- Fundamental
- Price
- TIGR $10.17
- GYRE $7.49
- Analyst Decision
- TIGR Buy
- GYRE
- Analyst Count
- TIGR 2
- GYRE 0
- Target Price
- TIGR $8.54
- GYRE N/A
- AVG Volume (30 Days)
- TIGR 6.7M
- GYRE 188.1K
- Earning Date
- TIGR 08-29-2025
- GYRE 08-12-2025
- Dividend Yield
- TIGR N/A
- GYRE N/A
- EPS Growth
- TIGR 93.97
- GYRE N/A
- EPS
- TIGR 0.46
- GYRE 0.02
- Revenue
- TIGR $374,147,409.00
- GYRE $100,643,000.00
- Revenue This Year
- TIGR $53.82
- GYRE $21.04
- Revenue Next Year
- TIGR $13.18
- GYRE $89.64
- P/E Ratio
- TIGR $22.31
- GYRE $96.96
- Revenue Growth
- TIGR 61.42
- GYRE N/A
- 52 Week Low
- TIGR $3.36
- GYRE $6.11
- 52 Week High
- TIGR $14.48
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- TIGR 62.94
- GYRE 42.81
- Support Level
- TIGR $8.98
- GYRE $7.49
- Resistance Level
- TIGR $10.99
- GYRE $7.80
- Average True Range (ATR)
- TIGR 0.62
- GYRE 0.48
- MACD
- TIGR 0.11
- GYRE 0.07
- Stochastic Oscillator
- TIGR 73.83
- GYRE 40.48
About TIGR UP Fintech Holding Ltd representing fifteen
UP Fintech Holding Ltd is an online brokerage firm focusing on Chinese investors. Its trading platform enables investors to trade in equities and other financial instruments on multiple exchanges of stocks and other derivatives. The company offers its customers brokerage and value-added services, including trade order placement and execution, margin financing, account management, investor education, community discussion, and customer support.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.